Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical diagnostic laboratory tests

This article was originally published in The Gray Sheet

Executive Summary

National coverage policies for 23 lab tests would become effective 12 months following publication of a final rule, according to a March 10 proposed rule establishing "national coverage and administrative policies" for diagnostic lab tests payable under Medicare Part B. The policies were finalized last September by an 18 member negotiated rulemaking committee (1"The Gray Sheet" Sept. 6, p. 11). Once it becomes effective, the rule provides a 12-month grace period "for any system changes any party is required to make." Comments are due by May 9

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel